Mills GB - Search Results

1

Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression.

Murph M, Mills GB. Murph M, et al. Among authors: mills gb. Expert Rev Mol Med. 2007 Oct 15;9(28):1-18. doi: 10.1017/S1462399407000476. Expert Rev Mol Med. 2007. PMID: 17935635 Review.

2

Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.

Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB. Fang X, et al. Among authors: mills gb. Ann N Y Acad Sci. 2000 Apr;905:188-208. doi: 10.1111/j.1749-6632.2000.tb06550.x. Ann N Y Acad Sci. 2000. PMID: 10818454 Review.

3

Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor.

Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. Hasegawa Y, et al. Among authors: mills gb. J Biol Chem. 2003 Apr 4;278(14):11962-9. doi: 10.1074/jbc.M209168200. Epub 2003 Jan 27. J Biol Chem. 2003. PMID: 12554733 Free article.

4

The emerging role of lysophosphatidic acid in cancer.

Mills GB, Moolenaar WH. Mills GB, et al. Nat Rev Cancer. 2003 Aug;3(8):582-91. doi: 10.1038/nrc1143. Nat Rev Cancer. 2003. PMID: 12894246 Review.

5

Targeting PI3K-AKT pathway for cancer therapy.

Lu Y, Wang H, Mills GB. Lu Y, et al. Among authors: mills gb. Rev Clin Exp Hematol. 2003 Jun;7(2):205-28. Rev Clin Exp Hematol. 2003. PMID: 14763163 Review.

6

Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.

Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB, Fang X. Liu S, et al. Among authors: mills gb. J Biol Chem. 2004 Dec 3;279(49):51075-81. doi: 10.1074/jbc.M408607200. Epub 2004 Oct 1. J Biol Chem. 2004. PMID: 15466414 Free PMC article.

7

Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.

Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Koul D, et al. Among authors: mills gb. Mol Cancer Ther. 2005 Nov;4(11):1681-8. doi: 10.1158/1535-7163.MCT-05-0258. Mol Cancer Ther. 2005. PMID: 16275989

8

Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.

Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, Murakami-Murofushi K, Koh E, Bandle RW, Byun HS, Bittman R, Fan D, Murph M, Mills GB, Tigyi G. Baker DL, et al. Among authors: mills gb. J Biol Chem. 2006 Aug 11;281(32):22786-93. doi: 10.1074/jbc.M512486200. Epub 2006 Jun 16. J Biol Chem. 2006. PMID: 16782709 Free PMC article.

9

Point mutations of protein kinases and individualised cancer therapy.

Davies M, Hennessy B, Mills GB. Davies M, et al. Among authors: mills gb. Expert Opin Pharmacother. 2006 Nov;7(16):2243-61. doi: 10.1517/14656566.7.16.2243. Expert Opin Pharmacother. 2006. PMID: 17059381 Review.

10

Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer.

Murph M, Tanaka T, Liu S, Mills GB. Murph M, et al. Among authors: mills gb. Clin Cancer Res. 2006 Nov 15;12(22):6598-602. doi: 10.1158/1078-0432.CCR-06-1721. Clin Cancer Res. 2006. PMID: 17121877 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,134 results

Search Page